[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 34
Citations 0
Comment & Response
October 2019

State-Level Approaches to Expanding Pharmacists’ Authority to Dispense Naloxone May Affect Accessibility

Author Affiliations
  • 1College of Pharmacy, The University of Texas at Austin
JAMA Intern Med. 2019;179(10):1442-1443. doi:10.1001/jamainternmed.2019.3653

To the Editor We read with great interest the recently published study by Abouk and colleagues1 that identified reduced opioid-related mortality in states granting pharmacists direct authority to dispense naloxone. We agree that empowering pharmacists to dispense naloxone can profoundly influence overdose risk and concur that the method of implementing such policies can greatly influence their effectiveness. However, categorizing naloxone access laws (NALs) as either providing pharmacists direct or indirect authority to dispense naloxone is an oversimplification. Based on this methodology, most states were grouped in the indirect category despite noteworthy state-to-state heterogeneity in implementation. Two recent studies, similarly designed and concurrently published in JAMA,2,3 assessed the influence of Texas’ and California’s NALs on naloxone accessibility from community pharmacies. The surprisingly divergent results highlight the importance of how NALs are implemented.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×